alprostadil (indicated in peripheral arterial occlusive diseases)

As the list published 23 Sept 2026 has it, binding since 5 Oct 2023. Each entry binds six months after its own publication date (Article 107c(7) of Directive 2001/83/EC).

What the list says

EU reference date: 28 Nov 1984
PSUR frequency: 8 years
Data lock point: 31 Jul 2030
Submission date: 29 Oct 2030
Next data lock point: Not stated
Next submission date: Not stated
Products covered: Nationally authorised (NAP)

Are PSURs required for products referred to in Articles 10(1), 10a and 16a of Directive 2001/83/EC?

No — the list does not require PSURs for these products.

The list asks this as one question for Articles 10(1), 10a and 16a together, and does not answer it for Article 14 at all. A PSUR may in any case be required at the request of a competent authority or as a condition of the marketing authorisation.

Notes in the list

PSUR frequency amended and DLP updated on 05/04/2023 DLP and information included in column "Are PSURs required for products referred to in Articles 10(1), 10a, 14, 16a of Directive 2001/83/EC as amended?" were updated on 07/05/2018 PRAC representative and Lead Member State were added on 30/01/2017

Track dates like these for your own products: a sample workspace, read-only, no account needed.

Try the demo

The next three reports

Data lock point 31 Jul 2030Submission by 29 Oct 2030
Data lock point 31 Jul 2038Submission by 29 Oct 2038
Data lock point 31 Jul 2046Submission by 29 Oct 2046

Counted from the data lock point the list gives, on the cycle it states: the submission date is 90 days after the data lock point — 70 days for a cycle of twelve months or less, 90 days for a longer one, as GVP Module VII sets out.

In earlier versions of the list

EMA/630645/2012 Rev.164 · published 23 Sept 2026
alprostadil (indicated in peripheral arterial occlusive diseases) — every 8 years, data lock point 31 Jul 2030
EMA/630645/2012 Rev.156 · published 4 Feb 2026
alprostadil (indicated in peripheral arterial occlusive diseases) — every 8 years, data lock point 31 Jul 2030

Source: European Medicines Agency, list of EU reference dates and frequency of submission of periodic safety update reports, EMA/630645/2012 Rev.164, published 23 Sept 2026. Open the published file

Kreastel is a planning and oversight aid for pharmacovigilance obligations. It tracks dates like these for a marketing authorisation holder's own products.

Report a discrepancy — if this page and the published file disagree, the file is right and we want to know.

Kreastel